We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Slaps Second Impax Plant with a Form 483

FDA Slaps Second Impax Plant with a Form 483

August 20, 2014

Impax received its second Form 483 in less than a week for a poor inspection of its U.S. manufacturing facility, igniting fresh doubts about the company’s plan to win approval of its Parkinson’s drug Rytary.

The brand and generics drugmaker disclosed August 4 the citation issued July 31 to its Hayward, Calif., plant following a June to July inspection that uncovered quality violations such as failing to review batch problems.

The notice came just days after the FDA slapped the company’s Taiwan plant with a separate Form 483 for failing to reject contaminated batches and properly validating equipment.

The FDA observed, for example, that Impax’s October 2012 laboratory report on release testing of a lot of pyridostigmine bromide tablets was out of specification. But the facility didn’t address the ramifications of generating the OOS result and whether it impacted other manufacturing operations, the FDA said.

Impax also was dinged for several repeat observations, such as failing to test whether generic products are equivalent to their branded counterpart.

Several products lacked an equivalency assessment, including orphenadrine citrate ER tablets, bupropion HCl ER tablets, oxybutynin HCl ER and rimantadine HCl tablets, the agency said.

Another repeat observation centered on poor data integrity, an area receiving heightened scrutiny from the FDA.

The plant has two spectrophotometers that don’t have adequate controls to ensure analysts can’t rewrite or delete analytical data. The systems are used in testing raw materials, stability and release.

Investigators also found a walk-in stability chamber in disrepair. The agency found rust stains on the metallic floor underneath rubber floor mats, a sagging ceiling tile and corrosion on a drain pan, according to the Form 483 with seven observations. The chamber is used to store products for stability studies.

Impax said that it was working to address the FDA’s latest observations and would respond to the agency in roughly two weeks.

It remains unclear how this latest development will impact the drugmaker’s hopes to get approval of its NDA for Rytary (IPX066).

Rytary was rejected by the FDA last year due to continuing problems at the Hayward plant. While Impax resubmitted the NDA, continuous delays in getting regulatory approval led to GlaxoSmithKline’s exit from a development and marketing partnership surrounding Rytary.

To read the Form 483, visit www.fdanews.com/ext/resources/files/08/08-04-14-Impax483.pdf. — Robert King

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing